GlassScriptPhysician profile
Thomas G Salvi
NPI 1902899461
$20,190.51
in general payments reported to CMS, 2019-2025
52 companies · $4,460 in 2025
The $4,460 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $1,421 · 2021: $2,879 · 2022: $2,967 · 2023: $3,403 · 2024: $4,328 · 2025: $4,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $56.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,135.28 |
| Education | $56.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,157.50 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,107.45 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,679.97 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $1,571.06 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,506.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,353.22 | 2020-2025 | |
| Amgen INC. | $1,204.37 | 2019-2025 | Prolia, Repatha, Otezla |
| Glaxosmithkline, LLC. | $966.13 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $771.17 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $720.66 | 2019-2025 | Spravato, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $493.62 | 2020-2025 | Trintellix |
| Corcept Therapeutics | $492.74 | 2024-2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $433.33 | 2022-2025 | Nuzyra, Xhance |
| Novartis Pharmaceuticals Corporation | $427.01 | 2021-2025 | |
| Lundbeck LLC | $384.98 | 2022-2025 | Rexulti |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Salvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.